Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

Jong Dai Kim; Cheol Young Park; Kue Jeong Ahn; Jae Hyoung Cho; Kyung Mook Choi; Jun Goo Kang; Jae Hyeon Kim; Ki Young Lee; Byung Wan Lee; Ji Oh Mok; Min Kyong Moon; Joong Yeol Park; Sung Woo Park

doi:10.1016/j.atherosclerosis.2014.01.015

Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

Jong Dai Kim
, Cheol Young Park
, Kue Jeong Ahn
, Jae Hyoung Cho
, Kyung Mook Choi
, Jun Goo Kang
, Jae Hyeon Kim
, Ki Young Lee
, Byung Wan Lee
, Ji Oh Mok
, Min Kyong Moon
, Joong Yeol Park
, Sung Woo Park

Kangbuk Samsung Hospital
Kyung Hee University
The Catholic University of Korea
Korea University
Hallym University
Sungkyunkwan University
Gachon University
Yonsei University
Soonchunhyang University
Seoul National University
University of Ulsan

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow^®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m²) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

Original language	English
Pages (from-to)	146-151
Number of pages	6
Journal	Atherosclerosis
Volume	234
Issue number	1
DOIs	https://doi.org/10.1016/j.atherosclerosis.2014.01.015
State	Published - May 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aspirin resistance
Atherogenic dyslipidemia
Diabetes
Non-HDL cholesterol

Access to Document

10.1016/j.atherosclerosis.2014.01.015

Cite this

Kim, J. D., Park, C. Y., Ahn, K. J., Cho, J. H., Choi, K. M., Kang, J. G., Kim, J. H., Lee, K. Y., Lee, B. W., Mok, J. O., Moon, M. K., Park, J. Y., & Park, S. W. (2014). Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. Atherosclerosis, 234(1), 146-151. https://doi.org/10.1016/j.atherosclerosis.2014.01.015

@article{9f7390c3145d47b29b1dd398451b4690,

title = "Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes",

abstract = "Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow{\textregistered}. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8\%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95\% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8\%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.",

keywords = "Aspirin resistance, Atherogenic dyslipidemia, Diabetes, Non-HDL cholesterol",

author = "Kim, \{Jong Dai\} and Park, \{Cheol Young\} and Ahn, \{Kue Jeong\} and Cho, \{Jae Hyoung\} and Choi, \{Kyung Mook\} and Kang, \{Jun Goo\} and Kim, \{Jae Hyeon\} and Lee, \{Ki Young\} and Lee, \{Byung Wan\} and Mok, \{Ji Oh\} and Moon, \{Min Kyong\} and Park, \{Joong Yeol\} and Park, \{Sung Woo\}",

year = "2014",

month = may,

doi = "10.1016/j.atherosclerosis.2014.01.015",

language = "English",

volume = "234",

pages = "146--151",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

AU - Kim, Jong Dai

AU - Park, Cheol Young

AU - Ahn, Kue Jeong

AU - Cho, Jae Hyoung

AU - Choi, Kyung Mook

AU - Kang, Jun Goo

AU - Kim, Jae Hyeon

AU - Lee, Ki Young

AU - Lee, Byung Wan

AU - Mok, Ji Oh

AU - Moon, Min Kyong

AU - Park, Joong Yeol

AU - Park, Sung Woo

PY - 2014/5

Y1 - 2014/5

N2 - Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

AB - Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

KW - Aspirin resistance

KW - Atherogenic dyslipidemia

KW - Diabetes

KW - Non-HDL cholesterol

UR - https://www.scopus.com/pages/publications/84897939773

U2 - 10.1016/j.atherosclerosis.2014.01.015

DO - 10.1016/j.atherosclerosis.2014.01.015

M3 - Article

C2 - 24657383

AN - SCOPUS:84897939773

SN - 0021-9150

VL - 234

SP - 146

EP - 151

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -

Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this